Coloplast A/S (CLPBF) Stock

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Coloplast A/S is headquartered in DK.

Coloplast A/S (CLPBF) stock trades at $64.00 with a market capitalization of $13.27B. The stock is valued at a price-to-earnings (P/E) ratio of 44.09, price-to-book of 7.23, price-to-sales of 3.31. Over the past 52 weeks the stock has ranged between $56.81 and $98.58, and currently trades 35.1% below its 52-week high. It pays a dividend yielding 2.42%.

On profitability, Coloplast A/S generates a return on equity (ROE) of 14.23%, above the typical market average, return on capital employed of 18.25%, an operating margin of 26.47%, a net profit margin of 7.51%.

Official website: www.coloplast.com